Skip to main content
. 2022 Jan 12;11:e67872. doi: 10.7554/eLife.67872

Figure 1. Mesoderm and endoderm co-induction from hiPSCs using CHIR.

(a) Diagram showing the experimental design (b) Cells following Stage-1 differentiation expressed MIXL1 (Mesendodermal lineage), SOX17 (definitive endoderm), and NCAM1 (mesoderm). Scale bar = 125 μm. (c) Majority of SOX17 cells were also FOXA2+. Scale bar = 62.5 μm. (d) Fold change of hiPSCs for FOXA2 (n = 3 each; 4 vs 7, p < 0.001; 7 vs 10, p < 0.001; 4 vs 10, p < 0.001), SOX17 (n = 3 each; 4 vs 7, p < 0.001; 7 vs 10, p < 0.001; 4 vs 10, p = 0.9978) and NCAM1 (n = 3 each; 4 vs 7, p < 0.001; 7 vs 10, p < 0.001; 4 vs 10, p < 0.001). All data are mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. ‘n’ refers to biological replicates. Diagram created using BioRender (http://biorender.com/).

Figure 1—source data 1. Raw data for Figure 1d.

Figure 1.

Figure 1—figure supplement 1. Primitive streak induction from hiPSCs using CHIR.

Figure 1—figure supplement 1.

(a) Diagram showing the experimental design. (b) Pluripotent marker (OCT4) expression on hiPSCs prior to induction with CHIR. (c) Cells following 48 hr CHIR treatment expressed T (primitive streak), MIXL1 (Mesendodermal lineage) but not pluripotent (OCT4) marker. FACS analysis of cells for (d) T and (e) MIXL1. (f) Schematic diagram showing the experimental design for flow cytometry analysis at the end of Stage-2 co-differentiation. (g) Flow cytometry analysis of endoderm marker (SOX17) and mesodermal marker (CD13) on hiPSCs, cells differentiated from standard protocol with or without Activin A. Scale bar = 125 μm for 20 X images. Diagram created using BioRender (http://biorender.com/).